N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC50 of 0.38 μM and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure-activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro-benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure-activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.

[1]  Thomas Friedrich,et al.  Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ Channels , 2009, Molecular Pharmacology.

[2]  W. A. Wilson,et al.  N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A Novel, Selective KCNQ2/Q3 Potassium Channel Activator , 2008, Molecular Pharmacology.

[3]  M. Harhun,et al.  Expression and function of the K+ channel KCNQ genes in human arteries , 2011, British journal of pharmacology.

[4]  W. Frankel,et al.  Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. , 2003, Human molecular genetics.

[5]  Dirk Isbrandt,et al.  Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior , 2005, Nature Neuroscience.

[6]  Robin J. Leach,et al.  A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family , 1998, Nature Genetics.

[7]  V. Gribkoff.  The therapeutic potential of neuronal KCNQ channel modulators , 2003, Expert opinion on therapeutic targets.

[8]  W. Dalby-Brown,et al.  Kv7 (KCNQ) channel modulators and neuropathic pain. , 2007, Journal of medicinal chemistry.

[9]  Kortaro Tanaka,et al.  Disruption of the Epilepsy KCNQ2 Gene Results in Neural Hyperexcitability , 2000, Journal of neurochemistry.

[10]  V. Gribkoff.  The therapeutic potential of neuronal KV7 (KCNQ) channel modulators: an update , 2008 .

[11]  A. Wickenden,et al.  The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site , 2009, Neuroscience Letters.

[12]  S. Berkovic,et al.  A potassium channel mutation in neonatal human epilepsy. , 1998, Science.

[13]  G. Rigdon,et al.  KCNQ potassium channels: drug targets for the treatment of epilepsy and pain , 2004 .

[14]  F. Bretschneider,et al.  A reduced K+ current due to a novel mutation in KCNQ2 causes neonatal convulsions , 1999, Annals of neurology.

[15]  Mark Leppert,et al.  A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns , 1998, Nature Genetics.

[16]  B S Brown,et al.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.

[17]  D. A. Brown,et al.  Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.

[18]  James O McNamara,et al.  In Vivo Profile of ICA-27243 [N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a Potent and Selective KCNQ2/Q3 (Kv7.2/Kv7.3) Activator in Rodent Anticonvulsant Models , 2008, Journal of Pharmacology and Experimental Therapeutics.

[19]  S. Olesen,et al.  The KCNQ1 potassium channel: from gene to physiological function. , 2005, Physiology.